AM‐Pharma B.V. Company Profile

16:42 EDT 21st March 2018 | BioPortfolio

AM‐Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. AM‐Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a Phase II trial in Ulcerative Colitis – a form of inflammatory bowel disease – AM‐Pharma developed an innovative recombinant form of human Alkaline Phosphatase. This recombinant Alkaline Phosphatase will be used in future trials and for commercialization. AM‐Pharma raised €29.2M in Q4 2011, enabling AM‐Pharma to finalize the GMP production and the development through phase II.

News Articles [586 Associated News Articles listed on BioPortfolio]

NASDAQ OMX Nordic: Derivatives: Anticipated adjustment in Karo Pharma due to rights issue (24/17)

The following information is based on a press release from Karo Pharma AB (Karo Pharma) published on December 5, 2017 and may be subject to change. The board of Karo Pharma has proposed that the Ex...

Verona Pharma plc: Verona Pharma Reports Operational Update and Financial Results for Full Year Ended December 31, 2017

LONDON, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...

Verona Pharma plc: Verona Pharma to Announce Operational Update and Financial Results for Full Year ended December 31, 2017

LONDON, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ('Verona Pharma'), a clinical-stage biopharmaceutical company focused on developing and commercializing innovati...

Pharma Integrates 2017: A New Value Proposition for Pharma

London, UK, 22nd November 2017 / Sciad Newswire / Further insights from the podium as the Pharma Integrates panellists tackle changing product and technological developments and a new patient-payer ...

Tetra Bio-Pharma Inc.: Tetra Bio-Pharma Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc.

OTTAWA, ONTARIO -- (Marketwired) -- 03/19/18 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP)(OTCQB: TBPMF), today announced the completion of the previously announced acq...

Verona Pharma plc: Verona Pharma Provides Clinical Development Update

Accelerates top-line data readouts from ongoing clinical trials with RPL554 in COPD and CFLONDON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (Verona Pharma), a cli...

Aerogen Pharma, Lyomark Pharma to develop inhaled surfactant

Aerogen Pharma and Lyomark Pharma have joined forces to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with...

Eisai: UK gives pharma a poor deal, may invest elsewhere

The Japanese government warned shortly after the referendum last year that its domestic pharma companies may consider pulling investment as a result of Brexit, saying the country will lose its appeal ...

Drugs and Medications [238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [23 Associated PubMed Articles listed on BioPortfolio]

Bioanalytical outsourcing: transitioning from Pharma to CRO.

Moving pharma contracting into the era of accountability.

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar...

To Nutraceuticals and Back: Rethinking a Concept.

The concept of nutraceuticals as pharma-foods comes fromfar. This termismade fromthe two words "nutrient" and "pharmaceutical", was coined by Stephen DeFelice, and is defined as "a food or part of a f...

Rejuvenating the Face: An Analysis of 100 Absorbable Suture Suspension Patients.

Absorbable suture suspension (Silhouette InstaLift, Sinclair Pharma, Irvine, CA) is a novel, minimally invasive system that utilizes a specially manufactured synthetic suture to help address the issue...

Clinical Trials [76 Associated Clinical Trials listed on BioPortfolio]

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Companies [736 Associated Companies listed on BioPortfolio]

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

Laurantis Pharma Oy

Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies, ...

FranceMed Pharma

FranceMed Pharma is a Research, Development, FMCG Manufacturer and Global Marketing Company established since 1981. FranceMed Pharma owns Magicool® brand and the world-wide patents and technology. Fr...

Pharma Active

Pharmaceutical industry has become one of the fastest growing industry. With growth comes the need for experienced professionals and various resources such as clinical trial centres, toxicology centre...

More Information about "AM‐Pharma B.V." on BioPortfolio

We have published hundreds of AM‐Pharma B.V. news stories on BioPortfolio along with dozens of AM‐Pharma B.V. Clinical Trials and PubMed Articles about AM‐Pharma B.V. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AM‐Pharma B.V. Companies in our database. You can also find out about relevant AM‐Pharma B.V. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Corporate Database Quicklinks

Searches Linking to this Company Record